Delayed-onset muscle soreness: a pilot study to assess analgesic study design features

Neil Singla, Paul J. Desjardins, Evelyn B. Cosca, Cherri Parulan, Anne Arriaga, Kelly C. Poole, Dan M. Batz, Phoebe D. Chang

Abstract
Based on a thorough review of the available literature in the delayed-onset muscle soreness (DOMS) model, we identified multiple study design characteristics that are considered to be normative in acute pain research but have not been followed in a majority of published DOMS experiments. We designed an analgesic investigation using the DOMS model that both complied with current scientifically accepted standards for the conduct of analgesic studies and demonstrated reasonable assay sensitivity. This randomized, double-blind, placebo-controlled within-subject study compared the efficacy of topical diclofenac sodium 1% with a matching placebo in reducing pain associated with DOMS. After exercise, subjects reporting DOMS received topical diclofenac sodium gel 1% (DSG 1%) applied to one leg and placebo to the other every 6 hours for 48 hours. Pain intensity was assessed at rest, upon standing, and when walking in the 48 hours after initial drug application (T0). The primary end point was the reduction in pain intensity (SPID 24) on walking. Subjects receiving DSG 1% had less pain while walking compared with those receiving placebo at 24 hours (SPID 24 = 34.9 [22.9] and 23.6 [19.4], respectively; P = 0.032). This investigation used experimental techniques that have been vetted in the field of exercise physiology and superimposed techniques that are considered to be best practice in the field of analgesic research. Over time and with the help of colleagues in both fields of study, similar investigations will validate design features that impact the assay sensitivity of analgesic end points in DOMS models. In addition, the study confirmed the analgesic efficacy of topical DSG 1% over placebo in subjects experiencing DOMS.

Keywords: Delayed onset muscle soreness, DOMS, Diclofenac; Topical NSAIDS, Analgesic methodology, Analgesic clinical trials

1. Introduction
Delayed-onset muscle soreness (DOMS) is an important experimental model and clinical pain state that has been used extensively to evaluate the analgesic efficacy of various oral drugs, topical agents, and devices. Most published DOMS studies primarily report physiologic (strength, swelling, metabolic rate, and range of motion) and laboratory (creatinine kinase, leukocyte infiltration, and immunohistochemistry) end points. Analgesic end points (muscle pain and/or muscle soreness) are also assessed in some of these published studies. Based on our review of the literature, we assert that although most published DOMS investigations have been well designed to evaluate physiologic and laboratory end points, they have not been optimally designed to evaluate analgesic end points. In Table 1, we select, analyze, and critique the analgesic design features of 15 high-quality recently published DOMS investigations.

Pain is a subjective end point that is measured by a variety of scales. Analgesic study outcomes are reported using an assortment of calculations derived from these scales. It is therefore critical that analgesic investigations prespecify the following: (1) a primary end point, (2) the scale that will be used to measure that primary end point, and (3) the method by which the significance of that primary end point will be calculated. However, several recently published DOMS investigations do not comply with this requirement (Table 1). Studies that report positive analgesic outcomes but have not clearly prespecified how those outcomes will be evaluated are subject to type I error (falsely positive conclusions). Recently published DOMS investigations may also have issues with type II error (false negative conclusions) secondary to low assay sensitivity. A study’s assay sensitivity is defined as its ability to detect a treatment difference between an efficacious drug and placebo. There have been several DOMS studies on drugs with known efficacy or on drug reformulations (with presumed efficacy) that nevertheless have reported negative analgesic findings. Negative study results can then be explained either as true negatives (the study product in the question does not work to treat DOMS) or false negatives (the study product works but the investigation lacks the assay sensitivity to detect a treatment effect).

Table 1

| Study | Design | Primary End Point | Scale | Type of Calculation | Compliance |
|-------|--------|-------------------|-------|---------------------|------------|
| Study A | Randomized, Double-Blind, Placebo-Controlled | Pain Intensity | SPID 24 | - | Yes |
| Study B | Randomized, Double-Blind, Placebo-Controlled | Pain Intensity | SPID 24 | - | Yes |
| Study C | Randomized, Double-Blind, Placebo-Controlled | Pain Intensity | SPID 24 | - | Yes |
| Study D | Randomized, Double-Blind, Placebo-Controlled | Pain Intensity | SPID 24 | - | Yes |
| Study E | Randomized, Double-Blind, Placebo-Controlled | Pain Intensity | SPID 24 | - | Yes |

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

© 2015 International Association for the Study of Pain. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

http://dx.doi.org/10.1097/j.pain.000000000000109
| Study | Title | Design | Study drug | Target muscle group | Analgesic end point(s) | Reported results for analgesic outcomes | Analysis and critique |
|-------|-------|--------|------------|---------------------|-----------------------|----------------------------------------|----------------------|
| Barlas et al. | Managing delayed-onset muscle soreness; lack of effect of selected oral systematic analgesics | Prospective, double-blind, randomized, placebo-controlled crossover group study. DOMS was induced on d 1, and then study drugs were given in 5 sequential periods after a prespecified washout. Total study N = 60 | Single dose of aspirin 900 mg, codeine 60 mg, paracetamol 1000 mg, placebo or control (no treatment) | Nondominant elbow flexors | Mechanical pain threshold tenderness, pain intensity VAS, and the McGill Pain Questionnaire were administered at various times | 3 study drugs of interest did not reduce pain more than placebo | The study design was difficult to understand by reading the manuscript. It was clear that the results were negative. Therefore, either the study lacked assay sensitivity or the drugs of interest were ineffective for the attenuation of DOMS. |
| Black et al. | Acute effects of dietary ginger on muscle pain induced by eccentric exercise | Prospective, double-blind, randomized, placebo-controlled 2-period crossover study. Subjects were exercised on the first study day. On the second study day, they received their first dose of study medication and performed another exercise bout. On the third study day, the opposite allocation of drug was administered. Total study N = 27 | Ginger 2 g once daily ×2 d or matching placebo | Nondominant elbow flexors | Pain intensity was assessed before and 45 min after ingestion of study drug through a 100-mm VAS | Ginger did not reduce muscle pain more than placebo | A 1-d washout in a 2-period crossover study is likely confounded by systemic drug effects and carryover muscle soreness. Regardless, the study results were negative, which indicates either that the investigation lacked assay sensitivity or that ginger was ineffective for the attenuation of DOMS. |
| Cannavino et al. | Efficacy of transdermal ketoprofen for delayed onset muscle soreness | Prospective, double-blind, randomized placebo-controlled study incorporating a mixed design: 8 subjects received placebo on both legs, 8 subjects received ketoprofen on both legs, and 16 subjects received placebo on one leg and ketoprofen on the other. Study product was applied immediately after exercise before the onset of DOMS. Total study N = 52 | Transdermal ketoprofen 10% cream 1 g applied every 8 h for 48 h or matching placebo | Quadriceps | Muscle soreness was evaluated at 24 and 48 h after exercise through a 10-point categorical soreness scale | Muscle soreness was decreased by ketoprofen for within-subject comparisons. Statistical significance was not reached for between-subject comparisons | There was a statistically significant effect for the within-subject comparison at 24 and 48 h. Comparisons were also made between subjects at multiple time points. The primary end point of the study was not prespecified. Because both within-patient and between-patient comparisons were made at 24 and 48 h, there was significant uncorrected multiplicity. |
| Drobnic et al. | Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva, Indena S.p.A., Milan, Italy): a randomised, placebo-controlled trial | Prospective, single-blind, randomized, placebo-controlled parallel group study. Study drug was administered 48 h before exercise and continued for 24 h after exercise. Total study N = 20 | Curcumin applied topically 1 g b.i.d. × 6 doses | Bilateral thigh and legs | Pain intensity was rated on a 4-point categorical scale at 8 different lower extremity locations (4 locations per leg) | Curcumin did not reduce muscle pain more than placebo | The study was single blind and as such inadequately controlled for bias. Regardless, the study results were negative, which indicates either that the investigation lacked assay sensitivity or that curcumin was ineffective for the attenuation of DOMS. |
| Hill et al. | Acute effect of 2 topical counterirritant creams on pain induced by delayed-onset muscle soreness | Prospective, single-blind, randomized, placebo-controlled parallel group study. Study drug was applied to subjects with established DOMS 48 h after exercise. Total study N = 54 | Single application of 2 mL of either capsaicin, menthol/methyl salicylate, or placebo | Nondominant elbow flexor | Reduction in pain 15 min after cream application measured by a 100-mm VAS | Positive P value for menthol/methyl salicylate vs placebo (P < 0.05) but not for placebo vs capsaicin | The study seems to be single blind. The various formulations had distinct smell and texture characteristics, which likely undermined the single-blind. Analgesic data were only captured for 15 min after drug application | (continued on next page)
### Table 1 (continued)

| Study                  | Title                                                                 | Design                                                                 | Study drug                                      | Target muscle group  | Analgesic end point(s)                                                                 | Reported results for analgesic outcomes                                                                 | Analysis and critique                                                                 |
|------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------------|----------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Hurley et al.          | The effect of caffeine ingestion on delayed onset muscle soreness    | Prospective, double-blind, randomized, placebo-controlled, 2-period crossover study. Study drug was administered before exercise in period 1. After a 7-d washout, DOMS was induced again in period 2 and the opposite allocation drug was administered. Total study N = 9 | Caffeine (5 mg /kg) daily for 5 d per period or matching placebo | Elbow                | Three measures were collected (muscle soreness, muscle soreness with palpation, and muscle fatigue) at the following time points: pre-exercise, 24, 48, 72, 96, and 120 h after exercise. All 18 measures were collected through 10-point categorical scales | Muscle soreness with and without palpation were decreased (P < 0.05) at several time points | Three measures were collected at 6 time points. Daily results were compared along with changes in daily reports from baseline. Therefore, 36 comparisons were made. The study reported positive results (P ≦ 0.05) for some comparisons. However, the study did not prespecify the primary end point or its method of calculation giving rise to significant uncorrected multiplicity |
| Hyldahl et al.         | Effects of ibuprofen topical gel on muscle soreness                  | Prospective, double-blind, randomized, placebo-controlled, 2-period crossover study. Study drug was applied 36 h after exercise to subjects with established DOMS in period 1. After a 3-wk washout, DOMS was induced again in period 2 and the opposite allocation of drug was applied. Total study N = 106 | Ibuprofen 10% gel (2" ribbon consisting of 125 mg of drug) or matched placebo every 6 h as needed for up to 10 applications per period | Elbow and knee flexors | Reduction in muscle pain/ soreness from baseline (first application of drug) over 60 h measured by a 100-mm VAS. Evaluations performed at 36, 37, 38, 39, 40, 41, 42, 48, 60, 66, 72, 84, 90, 96 and 108 h after exercise | Ibuprofen gel did not reduce muscle soreness more than placebo | The study results were negative, which indicates either that the investigation lacked assay sensitivity or that ibuprofen gel was ineffective for the attenuation of DOMS |
| Lecomte et al.         | A randomized controlled trial of the effect of naproxen on delayed onset muscle soreness and muscle strength | Prospective, double-blind, randomized, placebo-controlled, 2-period crossover study. Study drug was administered 24 h after exercise to subjects with established DOMS in period 1. After a 7-d washout, DOMS was induced again in period 2 and the opposite allocation of drug was administered. Total study N = 108 | Naproxen 500 mg b.i.d. × 7 d per period or matched placebo                                      | Quadriceps           | Muscle soreness measured by a 0- to 10 numeric rating scale assessed before drug administration and then subsequently 1, 2, 3, 4, 5, 6 and 7 d after drug administration | Muscle soreness was decreased in the naproxen group on d 3 when compared with placebo (P < 0.05) | The study assessed muscle soreness on 7 separate occasions. The investigation’s primary analgesic end point (time frame or method of calculation) was not prespecified giving rise to significant uncorrected multiplicity. A single positive finding of reduced soreness on d 3 is interesting but not robust |
| Mayer et al.           | Continuous low-level heat wrap therapy for the prevention and early phase treatment of delayed-onset muscle soreness of the low back: a randomized controlled trial | Prospective, nonblind, randomized, comparator controlled, parallel group study. The total population was divided into 2 studies; one evaluating preventive therapy and the other evaluating treatment of established pain. Total study N = 67 | Study drug of interest was a 18 × 25-cm heat wrap; control was either a cold pack or flexibility exercises | Low back              | Low back pain was evaluated on a 6-point categorical verbal rating scale. The investigation’s primary end point (its scale, time course, and method of calculation) were clearly defined in the article | Heat wrap therapy reduced pain in the treatment substudy and inhibited pain generation in the prevention substudy (both P < 0.05) | The nature of this study did not allow for appropriate blinding. Significant bias cannot be ruled out. End points were clearly defined and described |

(continued on next page)
In the table above, we select and analyze 15 high-quality recently published DOMS investigations that were discovered in our review. Studies were only considered if they evaluated at least 1 analgesic end point. We acknowledge that other published investigations exist but assert that the above list is representative of the currently available literature.

| Study                  | Title                                                                 | Design                                                                 | Study drug                                      | Target muscle group | Analgesic end point(s)                      | Reported results for analgesic outcomes                                                                 | Analysis and critique                                                                 |
|------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------|---------------------|---------------------------------------------|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Paulsen et al.²⁹        | A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise | Prospective, double-blind, randomized, placebo-controlled parallel group study. Study drug or placebo was administered before exercise and for 9 subsequent days. The study incorporated a second exercise regimen 3 wk after the first (introducing a crossover design element) that did not involve drug therapy. Total study N = 33 | Celecoxib 200 mg b.i.d. x 9 d or matched placebo | Elbow flexors       | Muscle soreness was the sole analgesic end point. Soreness was assessed through a 100-mm VAS both with and without palpation at baseline and h 24, 48, 72, 96, 168, and 216 | Muscle soreness was decreased in the celecoxib group when compared with placebo (P = 0.04). | Muscle soreness was evaluated with and without palpation at multiple time points (total of 16 measures). The primary analgesic outcome (timeframe, method of calculation, or inclusion of palpation) was not prespecified giving rise to significant uncorrected multiplicity. This fact, along with the modest p value (P = 0.04), gives rise to doubt as to the soundness of the analgesic conclusions. This pooled analysis of 3 underpowered studies that were conducted with different designs is difficult to interpret. |
| Rother et al.²²         | Efficacy of epicutaneous Diractin (ketoprofen in Transfersome gel) for the treatment of pain related to eccentric muscle contractions | Pooled meta-analysis of 3 smaller underpowered prospective studies with various designs. Total study N = 48 | Ketoprofen cream 25 mg, oral ketoprofen 25 mg, and matching placebo | Elbow flexors       | Pain intensity was evaluated using a 100-mm VAS and a 4-point categorical pain intensity scale at multiple time points in the various investigations | Mixed                                                                                               | The timing and method of calculation of the primary end point were not prespecified giving rise to uncorrected multiplicity                                  |
| Sayers et al.²³         | Effect of ketoprofen on muscle function and sEMG activity after eccentric exercise | Prospective, double-blind, randomized placebo-controlled, parallel group study. A single dose of study drug was given 36 h after exercise in subjects with established DOMS. Efficacy measurements were recorded for 8 h. Total study N = 48 | Single dose of oral ketoprofen 100 mg, ketoprofen 25 mg or matching placebo | Elbow flexors       | Muscle soreness was decreased when compared with placebo (P < 0.01). | Muscle soreness was decreased in both ketoprofen groups when compared with placebo (P < 0.01). | The nature of this study did not allow for appropriate blinding. Analgesic end points were only assessed for 30 min. |
| Sumida et al.²⁴         | Hot gel packs and reduction of delayed-onset muscle soreness: 30 min after treatment | Prospective, nonblind, randomized, parallel group study. Study agent was applied to subjects with established DOMS 48 h after exercise. Total study N = 19 | Hot gel pack, cold gel pack, room temperature gel pack, no treatment | Non-dominant elbow flexor | Analgesic VAS 30 min after application of gel pack | Muscle pain was decreased 30 min after application of hot gel pack (P < 0.05). Cold and room temperature gel packs had no analgesic effect | Neither the timing of the primary end point (24 vs 48 h) nor its method of calculation (landmark analysis vs change from baseline) was prespecified giving rise to uncorrected multiplicity. The study collected 5 separate measures at 4 time points (20 measures) per period. The investigation’s primary analgesic outcome (specific measure, time frame, or method of calculation) was not prespecified giving rise to significant uncorrected multiplicity. |
| Tokmakidis et al.²⁵     | The effects of ibuprofen on delayed muscle soreness and muscular performance after eccentric exercise | Prospective, double-blind, randomized, placebo-controlled, parallel group study. Study drug was administered immediately after exercise before the onset of DOMS. Total study N = 19 | Motrin 400 mg every 8 h for 48 h or matching placebo | Hamstrings          | Muscle soreness was evaluated before exercise, at 24 and 48 h after exercise through a 10-point categorical soreness scale | Muscle pain was decreased by ibuprofen at 24 but not 48 h after exercise (P < 0.05) | Neither the timing of the primary end point (24 vs 48 h) nor its method of calculation (landmark analysis vs change from baseline) was prespecified giving rise to uncorrected multiplicity. The study collected 5 separate measures at 4 time points (20 measures) per period. The investigation’s primary analgesic outcome (specific measure, time frame, or method of calculation) was not prespecified giving rise to significant uncorrected multiplicity. |
| Udani et al.²⁶          | BounceBack capsules for reduction of DOMS after eccentric exercise: a randomized, double-blind, placebo-controlled, crossover pilot study | Prospective, double-blind, randomized, placebo-controlled, crossover study. Study drug was given for 30 d before exercise. Measures were recorded for 72 h after exercise. After a 2-wk washout, the opposite allocation of drug was administered in period 2. Total study N = 10 | BounceBack 779 mg oral tablets daily × 30 d or matching placebo | Patellar tendon     | Pain intensity was measured on a 10-point VAS. Four subscales (current pain, least pain, most pain, and pain interference) along with pain on palpation were assessed at 6, 24, 48, and 72 h after exercise | Overall current pain (sum of 4 subscales) and least pain was significantly reduced (P < 0.05) by BounceBack at 6 and 48 h | The study collected 5 separate measures at 4 time points (20 measures) per period. The investigation’s primary analgesic outcome (specific measure, time frame, or method of calculation) was not prespecified giving rise to significant uncorrected multiplicity. |

Table 1 (continued)
Our hypothesis was that, in general, the latter was true; the high rate of negative findings in the DOMS model was secondary to nonoptimal analgesic study design and conduct. We identified multiple study design characteristics that are considered to be normative in acute surgical pain research that were not incorporated into a majority of recently conducted DOMS investigations. Specific examples include the following: (1) protocol-mandated baseline entry criteria requiring moderate or severe pain before randomization, (2) study-masking procedures to ensure that subjects were unaware of the baseline pain intensity values required for study entry, (3) attempts to control the placebo response, and (4) domiciling of subjects in research units where experimental controls (ie, dosing compliance, diary compliance, restricted ambulation) can be closely monitored during the primary efficacy evaluation period.

The purpose of this pilot study, then, was to attempt to design an analgesic investigation using the DOMS model that (1) controlled for type I error by complying with scientifically accepted standards of conduct for analgesic studies and (2) controlled for type II error by using vetted study design characteristics that are known to increase the assay sensitivity of acute surgical pain investigations. The pilot was designed after a thorough literature review, during which we were unable to locate any published peer-reviewed articles discussing analgesic methodological best practices relevant to DOMS.

To assess the assay sensitivity (risk of type II error) of our model, we selected diclofenac sodium topical gel 1% (DSG 1%, Voltaren Gel®), Novartis Consumer Healthcare, Inc., Parsippany, NJ as our study drug of interest and compared it with placebo. Topical DSG 1% is an agent with known analgesic efficacy that is approved in the United States for the treatment of pain associated with osteoarthritis.1,3,4 We therefore assumed that DSG 1% would have the ability to demonstrate analgesic efficacy in a DOMS model if appropriate study design characteristics were selected. To control for type I error, the primary end point of this pilot investigation was (1) prespecified, (2) measured using a validated 11-point numeric pain intensity scale, and (3) calculated using a well-understood efficacy paradigm (SPID 24).

2. Methods

2.1. Approvals and disclosures

Before any study-related activities, the investigation and its supporting documents (protocol, informed consent form, investigator brochure, and recruitment materials) were reviewed and approved by Aspire Institutional Review Board (IRB) (San Diego, CA). The requisite information was then listed on ClinicalTrials.gov (identifier: NCT02087748). Both the DSG 1% gel and the matching placebo were provided by Novartis Consumer Healthcare under an investigator-initiated research protocol and grant.

2.2. Study design and objectives

For the DOMS model under study, we selected the following design features: prospective, double blind, randomized, and placebo controlled. The analgesic efficacy of topical DSG 1% was compared with a matching placebo gel using a 1-period within-subject design. The prespecified primary efficacy end point of the study was the summed pain intensity difference (SPID) experienced by the subject while walking over the first 24 hours after drug application. The study also evaluated several secondary efficacy end points including SPID 24 and 48 at rest and upon walking.

2.3. Investigational plan

This study included a total of 24 healthy volunteer subjects (Fig. 1). An initial screening visit was scheduled during which all subjects first signed written informed consent and then underwent a placebo response education program. The program included a 15-minute video series followed by a written examination designed to evaluate the study subject’s understanding of the video modules. The key concepts covered in the video are described in Supplemental Table 1 (available online as Supplemental Digital Content at http://links.lww.com/PAIN/A41), and a more detailed overview of the program is included in the Discussion section. The education process was followed by a physical examination, medical history, and inclusion/exclusion review. Inclusion and exclusion criteria for this study had to be met at 2 separate time points (Fig. 1). One set of selection criteria was used before exercise, and the other set was used to determine the extent of pain immediately before randomization (Table 2).

2.4. Induction of delayed-onset muscle soreness

To create DOMS, all subjects performed a standardized repetitive quadriiceps muscle exercise in 3 phases using a Body-Solid GCEC340 machine (Body-Solid, Inc, Forest Park, IL). The exercise regimen was modified from the protocol described by Cannavino et al.5 and is detailed below.

2.4.1. Warm-up and determination of maximum tolerated weight

Subjects completed a warm-up of 4 sets of 10 regular body weight squat exercises from standing position (2 sets without weights and 2 sets with approximately 10-20 lbs of weight). The maximum tolerated weight (MTW) on the leg curl machine was then determined for each leg by having the subject do a full extension and flexion with resistance (1 leg at a time) starting with a low but reasonable weight selected by the study staff and increasing it with every repetition until subjects reached their MTW. The MTW is defined as the highest weight under which a subject could perform a full extension and flexion.

2.4.2. Workout: timed phase

Starting with the dominant leg, subjects performed 6 sets of 10 leg extension and flexion exercises with each leg on the leg curl machine under 80% of the MTW for that leg. Each repetition was performed through the full pain-free range of motion in a slow controlled manner. Subjects performed the concentric portion of the repetition for 2 seconds, paused at full contraction for 1 second, and then completed the eccentric portion over a 4-second period (for a total of 7 seconds per repetition). Subjects performed each set as tolerated and were given a rest period of 1 to 2 minutes in between sets. Repetitions were performed until subjects were unable to move the weight load through the full range of motion. If subjects were unable to complete the full 6 sets under 80% MTW, the weight was decreased in 5 pound increments until subjects could no longer complete 60% MTW, or 6 sets were completed.

2.4.3. Workout: untimed phase

Subjects completed untimed flexion-and-extension exercises (15-20 repetitions) beginning with the last weight used in the timed phase. The weights were gradually decreased in increments of 5 pounds until no weight was used. The same protocol was then performed on the subject’s opposite leg. Subjects were asked to report to the study center within 24 to 48 hours after exercise, at which time categorical and numeric pain ratings were recorded. The postexercise inclusion criteria
Table 2) were based on the subject’s pain scores at rest. To qualify, subjects (while at rest) needed to report a current categorical pain score of moderate or severe on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe) and a numerical pain intensity (NPRS: an 11-point numerical scale from 0 to 10 with 0 being no pain and 10 being the worst pain imaginable) of ≥4. Both right and left legs needed to meet these criteria, and the NPRS scores for each leg had to be within 3 points of each other. Subjects were unaware of the specific postexercise analgesic inclusion criteria before randomization.

If subjects met all postexercise inclusion criteria, they were randomized to receive 4 g of topical DSG 1% applied to the right leg and matching placebo gel to the left leg or 4 g of topical DSG 1% applied to the left leg and matching placebo gel to the right leg. Because the study was double blinded, each subject received 2 identical tubes of gel, 1 with active topical DSG 1% and the other with placebo gel marked either “right” or “left”. Each application of the gel thereafter followed the treatment assignment. Before each dose, the subject palpated the point of maximal tenderness (PMT) on each anterior thigh. The area was then marked using a template with a cutout area of 400 cm² centered over the PMT. The gels were applied to an area of 400 cm² every 6 hours for 48 hours.

To minimize the placebo response, the subject (and not the study nurse) applied the investigational product to their own legs. The application procedure was however witnessed by study staff to ensure compliance. Placebo and active gel were indistinguishable visually, by feel or by smell. The first study treatment application (T₀) was defined as the start time of the first application of study gel. Immediately after T₀, 3 separate baseline pain intensity measures were recorded (NPRS at rest, while standing, and while walking).

Subjects were confined to the study center for 24 hours and then discharged home with a paper diary. The NPRS scores (at rest, while standing, and while walking) were measured at the following time points: 3, 9, 15, 21, and 24 hours after T₀. To facilitate subject sleep, DOMS while standing and while walking were not collected between the hours of 11 PM and 5 AM. Pain intensity at rest was assessed with the subject resting quietly for at least 5 minutes before each assessment. Subjects were then asked to stand and rate their worst pain caused by standing in each leg independently. Finally, subjects were asked to walk approximately 5 m (16 feet) at a moderate pace and then rated their worst pain caused by walking in each leg independently.

Subjects were allowed to withdraw from the study at any time and for any reason. Rescue medication was not permitted. Ancillary analgesic techniques such as ice, heat, and massage were also prohibited. After discharge from the research center, subjects were educated to continue application of study gel or placebo to each specified leg every 6 hours until 48 hours after initiation of treatment. A paper
Table 2
Pre- and post-exercise inclusion and exclusion criteria.

**Inclusion criteria**

- Written informed consent provided before enrollment
- Between 18 and 35 y of age
- Not engaged in regular lower extremity fitness activities for more than 2 times per wk for ≥2 consecutive wk in the past 6 mo before screening
- Male subjects: not pregnant (subjects of child-bearing potential must have had a negative urine beta human chorionic gonadotropin (β-hCG) pregnancy test at screening), lactating, or planning to become pregnant for the duration of the study
- Female subjects: not pregnant (subjects of child-bearing potential must have had a negative urine β-hCG pregnancy test at screening)
- Willing and capable of understanding and complying with the requirements of the study
- Able to understand and communicate in English

**Exclusion criteria**

- Body mass index of ≥32 kg/m²
- History of active or suspected esophageal, gastric, pyloric channel, or duodenal ulceration or bleeding within 30 d preceding screening
- Psychiatric disease including major depression, bipolar disorder, or anxiety, or other medical condition that, in the opinion of the investigator, could interfere with the evaluation of the efficacy or safety of the study drug
- History of clinically significant cardiovascular, cerebrovascular, metabolic, pulmonary, neurological, hematological, autoimmune, psychiatric, or endocrine disorders, including type I or type II diabetes, or other clinically significant medical condition that, in the opinion of the investigator, may preclude safe study participation
- Previous surgery of the hips or knees within 6 mo before screening and/or scheduled surgery during the study participation
- Significant biomechanical abnormality in the lower extremity that would preclude study evaluations, such as peripheral or central neurological disease, significant back pain; symptomatic osteoarthritis of the hips, knee, or feet, or other painful conditions of the lower extremities
- Any type of orthopedic and/or prosthetic device or any skin abnormalities on the legs that may interfere with local tolerability
- Current treatment with corticosteroids, oral or topical analgesics, or anti-inflammatory drugs whose duration of action may affect study evaluations
- Malignancy in the last 5 y, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin that has been surgically cured, or any stage 1 cancer or carcinoma in situ cured by resection or localized radiation at least 5 y before screening with no evidence of recurrence
- History of allergy (cutaneous or systemic), hypersensitivity, or asthma to any of the following: diclofenac, paracetamol, acetylsalicylic acid, salicylic acid, other nonsteroidal anti-inflammatory drug or cyclooxygenase-2-specific inhibitor (coxib) or known cutaneous or systemic intolerance to any of the ingredients in the gel, such as isopropyl alcohol or propylene glycol
- History of known narcotic, analgesic, or alcohol abuse
- Any cognitive impairment that, in the opinion of the investigator, preclude study participation or compliance with study procedures (eg, Alzheimer dementia)
- Receipt of an investigational product within 30 d before the scheduled dose of study medication

**Postexercise/predose inclusion criteria**

- Report a delayed-onset muscle soreness (DOMS) score of moderate to severe for each leg on a scale of none, mild, moderate, or severe before randomization
- Receipt of an investigational product within 30 d before the scheduled dose of study medication

A follow-up visit was completed at 7 days (+1 day) after treatment initiation for end-of-study assessments.

Subjects completed a global assessment of analgesic efficacy for each leg at 24 hours, 48 hours, and the end-of-study visit. For this global assessment, subjects were asked to rate the study drug’s efficacy as poor, fair, good, very good, or excellent for each leg separately. Safety was assessed through reports of spontaneous adverse events, medical history findings, and physical examination results.

2.5. Statistical methodology

The primary analysis of efficacy and safety end points used an intention-to-treat (ITT) population, which included all participants in the group who were randomized and had at least 1 treatment application. All 24 subjects completed the trial with no missing doses. The primary efficacy end point was the SPID from baseline experienced by the subjects while walking over the first 24 hours after initiation of treatment (SPID_{0-24}). Secondary efficacy end points included SPID experienced over various time intervals while walking, at rest, or while standing. A complete statistical analysis plan was submitted to, and approved by, the Institutional Review Board before unblinding. Study drug was provided by Novartis Consumer Healthcare in a blinded fashion. The study center was not provided with the unblinded treatment code until after data lock was confirmed.

The following analyses were performed for all primary and secondary end points requiring SPID calculations:

1. A SPID was calculated for each leg (SPID-DSG and SPID-placebo) by applying the trapezoidal rule to the pain intensity differences from baseline (PIDs) over the relevant time frame.
2. For each subject, a difference in SPID values was calculated using the formula (SPID-DSG) – (SPID-placebo) = SPID-delta.
3. The mean and SD of the SPID-deltas was calculated.
4. Differences between the treatments (DSG vs placebo) were tested for all primary and secondary end points at the α = 0.05 level with 2-tailed paired t tests of the relevant SPID-delta values.

Because rescue therapy was not permitted and all 24 subjects completed the study, significant data imputation was not required. Missing assessments were primarily the result of subjects sleeping (the protocol mandated that only assessments at rest were to be performed between the hours of 11 PM and 5 AM). These missing data were interpolated using a linear best fit approach.

3. Results

3.1. Study population

Subjects were recruited over 5 weeks (March 12, 2014 to April 18, 2014). Subject disposition is described in the consort flow diagram (Fig. 1). Demographic and baseline characteristics of the ITT population are summarized in Table 3. The population was essentially young and healthy (mean age, 28 ± 3.5) without significant concomitant disease or medication intake. The distribution was approximately 2:1 male to female.
slightly more than 80% of subjects described their baseline pain intensity as “moderate.” The remaining subjects described their initial pain as “severe.” In most cases, subjects described a comparable level of pain in both legs.

### 3.2. Efficacy and safety assessments

The primary end point of the study (SPID$_{0-24}$ while walking) showed positive results. Subjects reported that legs receiving topical DSG 1% had a greater mean SPID score (ie, less pain) compared with those receiving placebo at 24 hours (34.9 vs 23.6, respectively; Student t test $P = 0.032$; SES $= 0.442$), suggesting good experimental assay sensitivity (Fig. 2 and Table 4). Multiple secondary efficacy end points (listed in Table 4) were also assessed. The mean SPID score between the DSG 1% group compared with the placebo group was statistically significant while walking at 48 hours (110.3 vs 86.8, respectively; Student t test $P = 0.025$) (Fig. 2). At rest, the difference in the mean SPID scores in subjects receiving topical DSG 1% compared with subjects receiving placebo at 24 hours was not statistically significant (28.1 vs 24.8, respectively; Student t test $P = 0.369$) (Fig. 2). Similarly, the difference in the mean “at rest” SPID scores at 48 hours was not significant (93.6 vs 83.8, respectively; Student t test $P = 0.330$). However, the difference in mean SPID scores between the treatment groups while standing was statistically significant at both 24 hours and 48 hours (33.9 vs 21.6 at 24 hours and 109.2 vs 82.2 at 48 hours; Student t test $P = 0.028$ at 24 hours and $P = 0.012$ at 48 hours).

Safety assessments were gathered by collecting all observed or reported adverse events and by examining the site of drug application. The exercise regimen, subsequent reversible muscle injury, and topical DSG 1% were well tolerated by all subjects. No subjects experienced any rash, irritation, or other adverse events during the study.

### 4. Discussion

The selected methodology for this pilot study demonstrated very good assay sensitivity, resulting in a positive $P$ value with only 24 subjects. It is difficult to determine which specific design elements contributed to the success of the study. To properly evaluate this question, it would be necessary to perform multiple studies changing only 1 design element at a time, while measuring the effect of that change on the investigation’s effect size. In the absence of this knowledge, we provide a discussion below with our opinions as to design elements that may have positively impacted experimental assay sensitivity. The purpose of providing these opinions is not to assert the effectiveness of any specific technique, but rather to begin a scientific discussion regarding the analgesic methodology of DOMS studies.

As previously stated, subjects were required to view a placebo response video education program before entering the trial. Analgesic studies on topical agents typically have reported high placebo response rates. This may be secondary to the physical effect of rubbing gel or cream onto the subject’s body. In our model, the placebo response rate was low enough to allow good assay sensitivity. Details regarding the placebo response video course are presented in Supplemental Table 1 (available online as Supplemental Digital Content at http://links.lww.com/PAIN/A41). After watching the video, subjects were required to take a written

---

**Table 3**

| Characteristic | Value |
|----------------|-------|
| Sex, n (%)     |       |
| Male           | 15 (62.5) |
| Female         | 9 (37.5) |
| Age, mean (SD) | 28 (3.5) |
| Race, n (%)    |       |
| Anglo-American | 13 (54) |
| African American | 9 (38) |
| Asian          | 2 (8) |
| Ethnicity, n (%) |     |
| Hispanic       | 7 (29) |
| Non-Hispanic   | 17 (71) |
| Footedness, n (%) |   |
| Right          | 20 (83) |
| Left           | 4 (17) |
| Baseline pain, n (%) | |
| Moderate in the treatment group | 20 (83) |
| Severe in the treatment group | 4 (17) |
| Moderate in the placebo group | 19 (79) |
| Severe in the placebo group | 5 (21) |

---

![Figure 2](image-url). Mean SPID scores in subjects with delayed-onset muscle soreness over the first 24 hours after drug application (SPID$_{0-24}$). * $P < 0.05$. **
Our theory regarding placebo response

The degree of trauma measured by physiologic and laboratory end points is documented in several high-quality experiments. Because our 1-period within-subject design was intended to replicate a portion of Cannavino’s experiment, we used an exercise regimen modeled after the program described in that article.8

5. Conclusions

This pilot investigation used experimental techniques that were developed and refined in the field of exercise physiology and superimposed techniques that are considered to be best practice in the field of analgesic research. The model exhibited excellent assay sensitivity and was safely conducted over a short period of time. Over time and with the help of colleagues in both fields of study, similar investigations will validate design features that impact the assay sensitivity of analgesic end points in DOMS models.

Conflict of interest statement

All authors, with the exception of Dr Desjardins, are full-time employees of Lotus Clinical Research, LLC (an analgesic research site and CRO). Dr N. Singla has received grants from

Table 4

Analgesic efficacy of topical diclofenac sodium gel 1% (DSG 1%) and placebo in patients with delayed-onset muscle soreness (DOMS).

| Treatment          | While walking | At rest       | While standing |
|--------------------|---------------|---------------|----------------|
|                    | SPID 24*      | SPID 48       | SPID 24        | SPID 48       | SPID 24     | SPID 48       |
| Topical DSG 1%     | 34.88 (22.86) | 110.25 (60.63) | 28.06 (23.84) | 93.56 (55.48) | 33.93 (23.29) | 109.19 (59.33) |
| Placebo            | 22.86 (19.38) | 86.75 (56.81)  | 24.81 (20.90) | 83.75 (53.60) | 21.62 (18.82) | 82.19 (51.34)  |
| SES                | 0.442         | 0.442         | 0.180          | 0.209         | 0.480       | 0.543         |
| P                  | 0.0324        | 0.0253        | 0.3688         | 0.3297        | 0.0275      | 0.0115        |

SPID scores are presented as mean (SD).
* Primary end point.
SES, standardized effect size; SPID, summed pain intensity difference.

examination. Test materials included (1) factual questions about study end points, (2) conceptual questions dealing with bias, investigator motivation, and subject motivation, and (3) real-world study vignettes. After subjects completed the exam, the test was graded and subjects were required to correct any errors. A predefined passing score was not set. Rather, the purpose of the examination was to stimulate a dialog between the investigator and subject regarding the study purpose, end points, and bias. If, based on this dialog, the investigator felt that the subject did not or could not comprehend critical study factors, the investigator had the discretion to screen-fail the subject (discretion was granted per protocol a priori). Subjects were trained at screening (with both video and test) and again on the day of randomization before T0 (video only).

The within-subject design used for this study doubled the sample size without a significant increase in the time or cost required to conduct the study. Most crossover studies require a 2-period design, which means that subject time commitment and research center resources are doubled. Because our design used both legs simultaneously, resource allocation required to increase the number of legs evaluated (from 24 legs to 48 legs) was fairly limited. Additionally, within-subject designs have been suggested to reduce intrasubject variability and may reduce the placebo response.6,8,21 Our theory regarding placebo response was that subject expectation may have been controlled by ensuring that the subject was aware that 1 leg was treated with an active drug whereas the other was not. High subject expectation leads to a placebo response.10

A study performed by Cannavino et al.8 simultaneously used a within-subject and between-subject design (Table 1). Their findings indicated that a within-subject design had far greater assay sensitivity than did a between-subject design. Our experiment was therefore modeled after the within-subject portion of the Cannavino study. Because DSG 1% was expected to have a local effect rather than a systemic effect, this design seemed appropriate. It is important to note, however, that a 1-period within-subject design is not feasible for most drugs (ie, systemically administered medications or topical agents with significant absorption and the potential for carryover effects).

In acute pain research, it is well documented that assay sensitivity is increased by randomizing only subjects who report moderate or severe pain.11,20 In this pilot, our postexercise criteria mandated that subjects report at least moderate pain at rest. Although our primary end point measured pain on walking (not at rest), we hypothesized that subjects who had moderate pain at rest might have a more robust pain state that is less susceptible to a placebo response and more amenable to a positive treatment response.

Significant care was taken to ensure that subjects were not aware of the specific postexercise analgesic criteria required for study entry. Because subjects received a stipend for study participation (and the specific amount was prorated based on the length of their study involvement), we attempted to ensure that reported postexercise entry scores were not manipulated by secondary motivations. If subjects inquired regarding the specifics of the requisite analgesic baseline entry criteria, study staff was instructed to respond as follows: “There are several baseline criteria that you must meet after exercise in order to qualify for continued study participation, but we are not allowed to disclose them.”

Selection of a primary end point that included pain upon movement (either pain while walking or while standing) as opposed to pain at rest seems to be an important design element for the maintenance of assay sensitivity. We observed a smaller effect size for pain at rest than for pain with movement (Table 4). It is probable that pain at rest is too mild to allow discrimination of analgesic effect. Pain while standing and while walking seem to have comparable assay sensitivity.

Subjects were housed at the research unit for the first 24 hours after drug application. Although subjects are domiciled within the research facility, experimental controls can be closely monitored. For example, ambulation can be regimented, correct dosing procedures and times can be observed, and assessments can be performed at verified times using verified mechanisms. It is probable that subject domiciling during the period of primary end point data capture augments an investigation’s assay sensitivity.

The exercise regimen is obviously a key component of any DOMS study. We found that the existing literature is replete with reversible muscle injury in a consistent, safe, and reproducible manner.9,17 The degree of trauma measured by physiologic and laboratory end points is documented in several high-quality experiments. Because our 1-period within-subject design was intended to replicate a portion of Cannavino’s experiment, we used an exercise regimen modeled after the program described in that article.8
Novartis Consumer Health, Inc, for consulting in the performance of clinical investigations. Dr Desjardins serves as an independent clinical research consultant to Lotus Clinical Research and to Novartis Consumer Healthcare. The other authors have no conflicts of interest to declare.

This investigator-initiated study was supported through a grant from Novartis Consumer Health, Inc.

Appendix A. Supplemental Digital Content

Supplemental Digital Content associated with this article can be found online at http://links.lww.com/PAIN/A41.

Article history:
Received 30 October 2014
Received in revised form 10 December 2014
Accepted 21 January 2015
Available online 28 January 2015

References

[1] Voltaren Gel (Diclofenac Sodium Topical Gel) 1%. Available at: www.voltarengel.com/common/pdf/Voltaren-PI-10-19.pdf. Accessed October 2009.

[2] Guidance for industry-analgesic indications: developing drug and biological products: services HaH. Rockville, Maryland: Center for Drug Evaluation and Research (CDER), Food and Drug Administration, 2014.

[3] Altman RD, Dreiser RL, Fisher CL, Chase WF, Dreher DS, Zacher J. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:1991–9.

[4] Baraf HS, Gloth FM, Barthel HR, Gold MS, Altman RD. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials. Drugs Aging 2011;28:27–40.

[5] Barlas P, Craig JA, Robinson J, Walsh DM, Baxter GD, Allen JM. Managing delayed-onset muscle soreness: lack of effect of selected oral systemic analgesics. Arch Phys Med Rehabil 2000;81:966–72.

[6] Barlow DH, Hayes SC. Alternating treatments design: one strategy for comparing the effects of two treatments in a single subject. J Appl Behav Anal 1979;12:199–210.

[7] Black CD, O’Connor PJ. Acute effects of dietary ginger on muscle pain induced by eccentric exercise. Phytother Res 2010;24:1620–6.

[8] Cannavan CR, Abrams J, Painikas LA, Saglimbeni A, Bracker MD. Efficacy of transdermal ketoprofen for delayed onset muscle soreness. Clin J Sport Med 2003;13:200–8.

[9] Drobnic F, Riera J, Appendino G, Togni S, Franceschi F, Valle X, Pons A, Tur J. Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial. J Int Soc Sports Nutr 2014;11:31.

[10] Haour F. Mechanisms of the placebo effect and conditioning. Neuroimmunomodulation 2005;12:195–200.

[11] Hartwick CT. Quality assessment in clinical trials: considerations for outcomes research in interventional pain medicine. Pain Pract 2008:8:433–8.

[12] Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000;60:555–74.

[13] JMaS HKD. Acute effect of 2 topical counterirritant creams on pain induced by delayed onset muscle soreness. J Sport Rehabil 2002;11:202–8.

[14] Hurley CF, Hatfield DL, Riebe DA. The effect of caffeine ingestion on delayed onset muscle soreness. J Strength Conds Res 2013;27:3101–9.

[15] Hyldahl RD, Keadle J, Rouzier PA, Pearl D, Clarkson PM. Effects of ibuprofen topical gel on muscle soreness. Med Sci Sports Exerc 2010;42:614–21.

[16] Lecomte JM, Lacronix VJ, Montgomery DL. A randomized controlled trial of the effect of naproxen on delayed onset muscle soreness and muscle strength. Clin J Sport Med 1998;8:82–7.

[17] Malm C, Sodin TL, Sjöberg B, Lenkevi R, Renstrom P, Lundberg IE, Ekblom B. Leukocytes, cytokines, growth factors and hormones in human skeletal muscle and blood after uphill or downhill running. J Physiol 2004;556:983–1000.

[18] Mayer JM, Mooney V, Matheson LN, Erasala GN, Verna JL, Udermann BE, Leggett S. Continuous low-level heat wrap therapy for the prevention and early phase treatment of delayed-onset muscle soreness of the low back: a randomized controlled trial. Arch Phys Med Rehabil 2006;87:1310–7.

[19] Paulsen G, Egner IM, Oranje M, Langberg H, Benestad HB, Fjeld JG, Hallen J, Raastad T. A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise. Scand J Med Sci Sports 2010;20:e195–207.

[20] Price DD, Bush FM, Long S, Harkins SW. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. PAIN 1994;56:217–26.

[21] Robey RR, Schultz MC, Inner CA. Single-subject clinical outcome research: designs, data, effect sizes and analyses. Aphasiology 1999;13:445–73.

[22] Rother M, Seidel EJ, Clarkson PM, Mazgareanu S, Viel U, Rother I. Efficacy of epicutaneous Diractin (ketoprofen in Transfersome gel) for the treatment of pain related to eccentric muscle contractions. Drug Des Devel Ther 2009;3:143–9.

[23] Sayers SP, Knight CA, Clarkson PM, Van Wegen EH, Kamen G. Effect of ketoprofen on muscle function and sEMG activity after eccentric exercise. Med Sci Sports Exerc 2001;33:702–10.

[24] Sumida KD, Greenberg MB, Hill JM. Hot gel packs and reduction of delayed onset muscle soreness 30 minutes after treatment. J Sport Rehabil 2003;12:221–8.

[25] Tokmakidis SP, Kokkinidis EA, Smilios I, Douda H. The effects of ibuprofen on delayed onset muscle soreness and muscular performance after eccentric exercise. J Strength Cond Res 2003;17:53–9.

[26] Udani JK, Singh BB, Singh VJ, Sandoval E. BounceBack capsules for delayed onset muscle soreness after eccentric exercise: a randomised, placebo-controlled trial. J Int Soc Sports Nutr 2009;6:14.